Amneal Pharmaceuticals Inc banner
A

Amneal Pharmaceuticals Inc
F:2DT

Watchlist Manager
Amneal Pharmaceuticals Inc
F:2DT
Watchlist
Price: 11.9 EUR 0.85% Market Closed
Market Cap: €3.7B

Amneal Pharmaceuticals Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Amneal Pharmaceuticals Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
A
Amneal Pharmaceuticals Inc
F:2DT
Research & Development
-$205.6m
CAGR 3-Years
0%
CAGR 5-Years
-3%
CAGR 10-Years
-12%
Johnson & Johnson
NYSE:JNJ
Research & Development
-$14.7B
CAGR 3-Years
-1%
CAGR 5-Years
-4%
CAGR 10-Years
-5%
Bristol-Myers Squibb Co
NYSE:BMY
Research & Development
-$9.5B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
-5%
Pfizer Inc
NYSE:PFE
Research & Development
-$10.4B
CAGR 3-Years
3%
CAGR 5-Years
-2%
CAGR 10-Years
-3%
Merck & Co Inc
NYSE:MRK
Research & Development
-$15.6B
CAGR 3-Years
-10%
CAGR 5-Years
-9%
CAGR 10-Years
-9%
Eli Lilly and Co
NYSE:LLY
Research & Development
-$13.3B
CAGR 3-Years
-23%
CAGR 5-Years
-17%
CAGR 10-Years
-11%
No Stocks Found

Amneal Pharmaceuticals Inc
Glance View

Market Cap
3.7B EUR
Industry
Pharmaceuticals

Amneal Pharmaceuticals Inc., birthed from the vision of two brothers, Chirag and Chintu Patel, stands today as a formidable entity in the generic and specialty pharmaceutical sector. Emerging from its modest beginnings in 2002 in Paterson, New Jersey, Amneal has embarked on a remarkable journey of growth and innovation. The company is best known for its strong portfolio of affordable generic medicines, which span a broad range of therapeutic areas. This ensures that they provide essential medications at more accessible prices, thus fulfilling a critical role in healthcare by making necessary treatments available to wider demographics. The company leverages vertical integration and cutting-edge manufacturing facilities to maintain high efficiency, allowing it to consistently produce and distribute pharmaceuticals on a global scale. Beyond generics, Amneal has diversified its operations to include complex drug delivery systems and specialty pharmaceuticals, carving out a niche in the more profitable segments of the pharmaceutical industry. By investing in research and development, the company continues to innovate, focusing particularly on high-barrier segments such as biosimilars and injectable medications. This strategic pivot not only enhances the company’s product offerings but also positions it more robustly against market volatilities. Amneal generates revenue by manufacturing and distributing its extensive product portfolio through partnerships with both retailers and health care facilities, ensuring a steady flow of sales. The company’s dual approach of maintaining a strong base in generics while exploring specialty and complex products shines a beacon on its strategic flexibility and its commitment to sustainable growth in the ever-evolving pharmaceutical landscape.

2DT Intrinsic Value
15.15 EUR
Undervaluation 21%
Intrinsic Value
Price
A

See Also

What is Amneal Pharmaceuticals Inc's Research & Development?
Research & Development
-205.6m USD

Based on the financial report for Sep 30, 2025, Amneal Pharmaceuticals Inc's Research & Development amounts to -205.6m USD.

What is Amneal Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-12%

Over the last year, the Research & Development growth was -44%.

Back to Top